Consider Humalog for your patients with type 2 diabetes
Do you have a patient with type 2 diabetes who...
- Needs rapid-acting insulin, in addition to long-acting insulin, to manage postmeal glucose levels?
- Is willing to add mealtime insulin injections to current basal insulin injections?
- Has long partnered well with you and kept to your treatment plan?
- Is ready to start mealtime insulin?
- Wants an insulin regimen that allows flexibility around family meals?
- Improved postmealtime glucose when added to a basal insulin1,2
- Should be injected 15 minutes before or immediately after the meal1
- Available in the Humalog U-100 KwikPen and Humalog U-200 KwikPen
Dosage of Humalog must be individualized. Humalog given by subcutaneous injection should generally be used in regimens with intermediate- or long-acting insulins.Learn more about Humalog ▶ Learn about Humalog U-100 self-titration dosing ▶ Learn more about the efficacy of Humalog ▶
With Humalog U-200 KwikPen, patients can have a mealtime insulin pen that lasts longer between pen changes*†
Consider Humalog U-200 KwikPen
- Is bioequivalent‡ to Humalog U-100; therefore, you should expect similar efficacy as Humalog U-1001
- Contains 600 units of rapid-acting insulin compared with the 300 units in a U-100 pen1
- Contains concentrated 200 U/mL insulin1
- Delivers the same dose in half the liquid volume*1
- Is the same size1 and familiar design as Humalog U-100 KwikPen
*As compared with U-100 mealtime insulin pens.
†Once opened, Humalog prefilled pens should be thrown away after 28 days, even if insulin remains.
‡As determined by area under the curve and maximum concentration.
Select Safety Information
Humalog, Humalog Mix75/25, and Humalog Mix50/50 are contraindicated during episodes of hypoglycemia and in patients who are hypersensitive to insulin lispro or any excipients contained in the formulation.